Age is often a predictor for morbidity and mortality. Although we previously proposed risk factors for adverse outcome in syncope, after accounting for the presence of these risk factors, it is unclear whether age is an independent risk factor for adverse outcomes in syncope. Our objective was to determine whether age is an independent risk factor for adverse outcome following a syncopal episode. We conducted a prospective, observational study enrolling consecutive patients with syncope. Adverse outcome/critical intervention included hemorrhage, myocardial infarction/percutaneous coronary intervention, dysrhythmia, antidysrhythmic alteration, pacemaker/defibrillator placement, sepsis, stroke, death, pulmonary embolus or carotid stenosis. Outcomes were identified by chart review and 30-day follow-up. We found that of 575 patients, adverse events occurred in 24%. Overall, 35% with risk factors had adverse outcomes compared to 1.6% without risks. Age ≥ 65 were more likely to have adverse outcomes: 34.5% versus 9.3%, p<0.001. Similarly, among patients with risk factors, elderly patients had more adverse outcomes: 43%; 36-50% versus 22%; 16-30%, p<0.001. However, among patients with no predefined risks, there were no statistical differences: 3.6%; 0.28-13% versus 1%; 0.04-3.8%. This was confirmed in a regression model accounting for the interaction between age>65 and risk factors. Although the elderly with syncope are at greater risk for adverse outcomes overall and in patients with risk factors, age ≥ 65 alone was not a predictor of adverse outcome in syncopal patients without risk factors. Based on this data, it may be safe to discharge home from the ED patients with syncope, but without risk factors, regardless of age.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.archger.2013.07.010DOI Listing

Publication Analysis

Top Keywords

risk factors
16
adverse outcomes
12
factors adverse
8
adverse outcome
8
age independent
8
independent risk
8
risk factor
8
factor adverse
8
adverse
7
risk
6

Similar Publications

Purpose Of Review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association.

View Article and Find Full Text PDF

Growing Pains: The Incidence and Prevalence of Myopia from 1950 to 2050.

J Binocul Vis Ocul Motil

January 2025

Ross Eye Institute, University at Buffalo, Buffalo, New York.

Myopia has been included as one of the five serious ocular conditions leading to blindness. Prevalence of myopia (between -0.50D and -5.

View Article and Find Full Text PDF

The role of the early-life gut microbiome in childhood asthma.

Gut Microbes

December 2025

Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital, Herlev-Gentofte, Gentofte, Denmark.

Asthma is a chronic disease affecting millions of children worldwide, and in severe cases requires hospitalization. The etiology of asthma is multifactorial, caused by both genetic and environmental factors. In recent years, the role of the early-life gut microbiome in relation to asthma has become apparent, supported by an increasing number of population studies, research, and intervention trials.

View Article and Find Full Text PDF

Objective: To quantify treatment preferences for food allergy management options (oral immunotherapy, biologic therapy, and allergen avoidance), overall and by sociodemographic strata.

Methods: A US general population (≥13 years) discrete choice experiment (DCE) conducted comprised of 12 treatment-feature focused DCE choice sets; the Intolerance of Uncertainty─12 Scale (IUS-12); and clinical/demographic questions. Conditional logistic regression analyses were conducted overall and by age, income, urbanization, educational attainment, food and other sociodemographic factors, and presented as odds ratios (ORs) with 95% confidence intervals (CIs).

View Article and Find Full Text PDF

Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Curr Med Res Opin

January 2025

Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!